Acasti Pharma (ACST) PT Lowered to $5 at Oppenheimer, Analyst Still Recommends "Building a Position" Given Multiple Upcoming Clinical Milestones
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell lowered the price target on Acasti Pharma (NASDAQ: ACST) to $5.00 (from $6.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
